Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1163 in healthy volunteers
NCT06103877Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Primary completion
- Jan 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of AZD1163 (20 arms), sponsored by AstraZeneca. Primary endpoint: Adverse Events at 450 days. Started Nov 2023; status: completed.
02
Drugs
AZD1163
Beyond the preview
Go deeper on NCT06103877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06103877.